Judith Kelleher Anderson, FounderJudith Kelleher-Andersson, Ph.D.
Founder, President and Chief Executive Officer (CEO)

"A therapy that is only neuroprotective will never be sufficient to halt or reverse  neurodegenerative disease progression." I came to this realization after working in the neuroscience field for over 20 years as a graduate student, as a post-graduate fellow and after working at three biotech companies, where I directed the discovery of therapeutics aimed at Alzheimer's disease and other neurodegenerative disorders. 
Read full message...


Neuronascent, Inc. has discovered and is developing disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease and Down syndrome. 

Our lead candidate for Alzheimer's and potentially Parkinson's disease, NNI-362,  not only shows efficacy, by increasing the number of new neurons that survive to maturity that is associated with a reversal in behavioral  impairment, but is also shown to be safe in all FDA required GLP safety tests. This "neuron-regenerative" agent crosses into brain, following oral administration and increases the number of new neurons through a unique mechanism-of-action, suggesting a first-in-class therapeutic aimed at reversing Alzheimer's disease.



Apr 2015 Neuronascent Secures Financing for Development of Its Alzheimer's Therapeutic. View Press Release

Feb 2015  Neuronascent Announces Expanded Patent Coverage In US and Russia For Its Alzheimer's Disease and Down Syndrome Therapeutics. View Press Release

Sep 2014 NI Research’s September 2014 Issue of NeuroPerspective fully reviews Alzheimer’s therapeutics and prominently mentions Neuronascent, Inc. In covering the different approaches to Alzheimer’s therapeutic development, the review notes that “The one neurogenesis-focused company prioritizing Alzheimer’s is Neuronascent.”   Click to purchase and download the full issue. NeuroPerspective publisher Dr. Harry Tracy also called Neuronascent “the neurogenesis specialist,” and he selected Neuronascent’s program as one of the ‘Top Ten’ CNS partnering opportunities to be presented at the Informa Therapeutic Area Partnerships conference, which will be held in Boston this November.

Apr 2014  Neuronascent Successfully Completes Pre-IND Meeting with FDA for Alzheimer’s Disease Therapeutic. View Press Release

More News

» Home
» News & Events
» Contact Us
Management Team
Directors & Advisors
Drug Discovery
Intellectual Property
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Down Syndrome
Hibernation and Ischemia
© 2014 NeuroNascent, Inc. - All Rights Reserved - Website by TeraMark
This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and involve risks and uncertainties that could cause actual results to differ materially from current expectations.